[{"Assets_0_Q3_USD":765145000.0,"CommonStockSharesOutstanding_0_Q3_shares":50533070.0,"NetCashProvidedByUsedInOperatingActivities_3_Q3_USD":-234713000.0,"NetIncomeLoss_1_Q3_USD":-87310000.0,"NetIncomeLoss_3_Q3_USD":-109785000.0,"StockholdersEquity_0_Q3_USD":662596000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q3_USD":11763000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_3_Q3_USD":35234000.0,"Ticker":"RARE","CIK":"1515673","name":"ULTRAGENYX PHARMACEUTICAL INC.","OfficialName":"Ultragenyx Pharmaceutical Inc. Common Stock","form":"10-Q","period":"20180930","fy":"2018.0","fp":"Q3","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"5418950849.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20181106"}]